X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (81) 81
oncology (75) 75
index medicus (72) 72
female (58) 58
male (51) 51
middle aged (45) 45
aged (44) 44
adult (41) 41
cancer (33) 33
chemotherapy (23) 23
tumors (21) 21
treatment outcome (20) 20
aged, 80 and over (18) 18
pharmacology & pharmacy (18) 18
animals (17) 17
medicine & public health (17) 17
antineoplastic agents - therapeutic use (16) 16
metastasis (16) 16
neoplasms - drug therapy (16) 16
clinical trials (15) 15
research (15) 15
carcinoma (14) 14
pharmacokinetics (14) 14
toxicity (13) 13
antineoplastic agents - adverse effects (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
maximum tolerated dose (12) 12
patients (12) 12
pharmacology/toxicology (12) 12
antineoplastic agents - administration & dosage (11) 11
france (11) 11
hematology, oncology and palliative medicine (11) 11
therapy (11) 11
trial (11) 11
antineoplastic agents - pharmacokinetics (10) 10
cell line, tumor (10) 10
expression (10) 10
mice (10) 10
solid tumors (10) 10
survival (10) 10
breast cancer (9) 9
cancer therapies (9) 9
care and treatment (9) 9
drug therapy (9) 9
efficacy (9) 9
life sciences (9) 9
metastases (9) 9
pharmacology (9) 9
squamous-cell carcinoma (9) 9
adolescent (8) 8
analysis (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
breast-cancer (8) 8
cetuximab (8) 8
colorectal neoplasms - drug therapy (8) 8
combination (8) 8
growth-factor receptor (8) 8
lung-cancer (8) 8
neoplasm staging (8) 8
ovarian cancer (8) 8
pembrolizumab (8) 8
prospective studies (8) 8
safety (8) 8
squamous cell carcinoma (8) 8
studies (8) 8
young adult (8) 8
asthenia (7) 7
complications and side effects (7) 7
dosage and administration (7) 7
head and neck neoplasms - drug therapy (7) 7
immunotherapy (7) 7
neoplasm metastasis (7) 7
phase i (7) 7
surgery (7) 7
vinblastine - analogs & derivatives (7) 7
vinorelbine (7) 7
antibodies, monoclonal, humanized - adverse effects (6) 6
anticancer properties (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
antineoplastic combined chemotherapy protocols - pharmacokinetics (6) 6
diarrhea (6) 6
docetaxel (6) 6
fluorouracil (6) 6
further section (6) 6
head (6) 6
infusions, intravenous (6) 6
multicenter (6) 6
nausea (6) 6
neoplasms - metabolism (6) 6
nivolumab (6) 6
open-label (6) 6
ovarian neoplasms - pathology (6) 6
oxaliplatin (6) 6
prognosis (6) 6
protein kinase inhibitors - adverse effects (6) 6
protein kinase inhibitors - therapeutic use (6) 6
radiotherapy (6) 6
recurrent (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1324 - 1334
Journal Article
Angewandte Chemie International Edition, ISSN 1433-7851, 04/2018, Volume 57, Issue 17, pp. 4668 - 4672
Herein we disclose the synthesis of original chiral scaffolds—ortho‐orientated terphenyls presenting two atropisomeric Ar–Ar axes. These unusual structures... 
axial chirality | sulfoxides | chiral ligands | atropisomerism | asymmetric C−H activation | CHEMISTRY, MULTIDISCIPLINARY | DYNAMIC KINETIC RESOLUTION | ALKENES | AXIALLY CHIRAL BIARYLS | OLEFINATION | asymmetric C-H activation | DERIVATIVES | CATALYZED DIRECT ARYLATION | ACRYLATES | Stereoselectivity | Ligands | Transformation | Activation | Axes (reference lines) | Terphenyls
Journal Article
Journal Article
Cancer Cell, ISSN 1535-6108, 06/2014, Volume 25, Issue 6, pp. 846 - 859
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 2, pp. 157 - 157
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 06/2018, Volume 105, Issue 6, pp. 596 - 602
The publication of the new WHO classification of head and neck tumours in 2017 brought major modifications. Especially, a new chapter is dedicated to the... 
Anatomical pathology | HNSCC | Classification | Head and neck | Human papilloma virus | WHO
Journal Article
ACS CATALYSIS, ISSN 2155-5435, 03/2019, Volume 9, Issue 3, pp. 2532 - 2542
Although chiral sulfoxides are important motifs in medicinal chemistry and asymmetric synthesis, design and applications of sulfoxide ligands are still... 
cyclopropane | AGOSTIC INTERACTIONS | ARYLATION | CHEMISTRY, PHYSICAL | DFT investigations | asymmetric C-H | BIS-SULFOXIDE LIGAND | OXIDATIVE ADDITION | C-H ACTIVATION | ARYLBORONIC ACIDS | aminosulfoxide | FUNCTIONALIZATION | enantioselective C(sp)-H activation | SULFINYL ANILINE | OLEFINS | BOND ACTIVATION
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 949 - 956
Summary Background Diffuse-type tenosynovial giant cell tumour (dt-GCT) of the soft tissue (alternatively known as pigmented villonodular synovitis), an orphan... 
Hematology, Oncology and Palliative Medicine | PIGMENTED VILLONODULAR SYNOVITIS | DIAGNOSIS | THERAPY | EFFICACY | ONCOLOGY | PERIORBITAL EDEMA SECONDARY | MACROPHAGES | RECEPTOR | ANTIBODY | ARTHRITIS | IMATINIB MESYLATE | Receptor, Macrophage Colony-Stimulating Factor - antagonists & inhibitors | Receptor, Macrophage Colony-Stimulating Factor - immunology | Giant Cell Tumors - immunology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Giant Cell Tumors - pathology | Soft Tissue Neoplasms - drug therapy | Male | Antineoplastic Agents - administration & dosage | Giant Cell Tumors - metabolism | Receptor, Macrophage Colony-Stimulating Factor - metabolism | Synovitis, Pigmented Villonodular - drug therapy | Synovitis, Pigmented Villonodular - pathology | Soft Tissue Neoplasms - immunology | Young Adult | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Drug Administration Schedule | Soft Tissue Neoplasms - metabolism | Synovitis, Pigmented Villonodular - metabolism | Treatment Outcome | Synovitis, Pigmented Villonodular - immunology | Giant Cell Tumors - drug therapy | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Infusions, Intravenous | Monoclonal antibodies | Macrophage colony stimulating factor | Tumors
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2018, Volume 103, p. 120
Introduction Cancer in the elderly is a major public issue. However, older patients have long been debarred from clinical trials. There is a high unmet medical... 
Elderly people | Adolescence | Medical research | Populations | Young adults | Medical services | Feasibility studies | Clinical trials | Statistics | Patients | Subgroups | Heterogeneity | Population (statistical) | Older people | Aging | Adults | Children | Adolescents | Elderly | Cancer | Geriatrics
Journal Article
by Cohen, Ezra E W and Cohen, Ezra and Soulières, Denis and Le Tourneau, Christophe and Dinis, Jose and Dinis, José and Licitra, Lisa and Ahn, Myung-Ju and Soria, Ainara and Machiels, Jean-Pascal and Mach, Nicolas and Mehra, Ranee and Burtness, Barbara Ann and Burtness, Barbara and Zhang, Pingye and Cheng, Jonathan and Swaby, Ramona F and Harrington, Kevin and Harrington, Kevin J and Acosta-Rivera, Mirelis and Adkins, Douglas R and Aghmesheh, Morteza and Airoldi, Mario and Aleknavicius, Eduardas and Al-Farhat, Yousuf and Algazi, Alain P and Almokadem, Salah and Alyasova, Anna and Bauman, Jessica R and Benasso, Marco and Berrocal, Alfonso and Bray, Victoria and Caponigro, Francesco and Castro, Ana and Cescon, Terrence P and Chan, Kelvin and Chaudhry, Arvind and Chauffert, Bruno and Csoszi, Tibor and De Boer, J.P and Delord, Jean-Pierre and Dietz, Andreas and Dupuis, Charlotte and Digue, Laurence and Erfan, Jozsef and Escobar Alvarez, Yolanda and Evans, Mererid and Fidler, Mary Jo and Forster, Martin David and Friesland, Signe and Ganti, Apar K and Geoffrois, Lionnel and Grant, Cliona and Gruenwald, Viktor and Hoffmann, Thomas and Horvai, Geza and Inciura, Arturas and Jang, Raymond and Jankowska, Petra and Jimeno, Antonio and Joseph, Mano and Juarez Ramiro, Alejandro and Karaszewska, Boguslawa and Kawecki, Andrzej and Keilholz, Ulrich and Keller, Ulrich and Kim, Sung-Bae and Kocsis, Judit and Kotecki, Nuria and Kozloff, Mark F and Lambea, Julio and Landherr, Laszlo and Lantsukhay, Yuri and Lazarev, Sergey Alexandrovich and Lee, Lip Way and Lifirenko, Igor Dmitrievich and Martincic, Danko and Matorin, Oleg Vladmirovhich and McGrath, Margaret and Misiukiewicz, Krzysztof and Morris, John C and Mufazalov, Fagim Fanisovich and Niu, Jiaxin and Pamoorthy Srinivasan, Devraj and Perez Segura, Pedro and Rauch, Daniel and Ribeiro, Maria Leonor and Rodriguez, Cristina and Rolland, Frederic and Russo, Antonio and Ruzsa, Agnes and Sanches, Frederico and Shin, Sang-Won and Shtiveland, Mikhail and Soulieres, Denis and Specenier, Pol and Szekanecz, Eva and Szota, Judit and van Herpen, Carla M.L and Velez-Cortes, Hector A and ... and Keynote-040 Investigators and KEYNOTE-040 investigators
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 156 - 167
There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour... 
CRITERIA | TRIAL | MEDICINE, GENERAL & INTERNAL | NIVOLUMAB | CANCER | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Docetaxel - adverse effects | Humans | Middle Aged | Squamous Cell Carcinoma of Head and Neck - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Cetuximab - therapeutic use | Cetuximab - adverse effects | Docetaxel - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Squamous Cell Carcinoma of Head and Neck - drug therapy | Female | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Disease Progression | Head and Neck Neoplasms - pathology | Methotrexate - adverse effects | Squamous Cell Carcinoma of Head and Neck - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cetuximab - administration & dosage | Methotrexate - administration & dosage | Aged | Methotrexate | Squamous cell carcinoma | Metastasis | Therapy | Toxicity | Perforation | Clinical trials | Oncology | Cancer therapies | Metastases | Skin cancer | Anticancer properties | Pembrolizumab | Randomization | Motivation | Platinum | Neck | Safety | Medical treatment | Fatigue | Hypothyroidism | Survival | Patients | Chemotherapy | Interactive systems | Large intestine | Head and neck cancer | Ligands | Tumors
Journal Article